Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, launch generic Aggrenox (aspirin/extended-release dipyridamole) capsules in the United States which are used to lower the risk of stroke in people who have had a mini-stroke (transient ischemic attack or TIA) or stroke due to a blood clot.
Stroke is caused when there is an interruption to the flow of oxygen rich blood to the brain. Without oxygen, brain cells can become damaged and die. Sudden bleeding in the brain can also cause a stroke if it damages brain cells. A stroke can result in brain damage, long-term disability, or even death. It is fifth leading cause of death in America. About 130,000 people die as the result of a stroke each year. Aggrenox capsules had annual sales of approximately $457 million in the United States.
Subscribe to PharmaTutor News Alerts by Email >>
